Platelet integrin glycoprotein IIb/IIIa inhibitors: Opportunities and challenges

Journal of Invasive Cardiology

Volumn 8, Issue SUPPL. B, 1996, Pages

  Tcheng, James E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002116799     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326:242-250.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326:310-318.
3. Waller BF. "Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters" - the future treatment of atherosclerotic coronary artery disease? A clinical-morphologic assessment. J Am Coll Cardiol 1989;13:969-87.
4. Waller BF, Orr CM, Pinkerton CA, et al. Coronary balloon angioplasty dissections:"The Good, The Bad and The Ugly". J Am Coll Cardiol 1992;20:701-706.
5. Steele PM, Chesebro JH, Stanson AW et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;7:105-112.
6. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
7. Roberts HR, Lozier JN. New perspectives on the coagulation cascade. Hosp Pract 1992;27:97-105, 109-112.
8. Coller BS. Blood elements at surfaces: Platelets. Ann N Y Acad Sci 1987;516:362-379.
9. Coller BS. Platelet in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE (eds). The Heart and Cardiovascular System: Scientific foundations. 2nd edition. New York: Raven Press, 1991;219-273.
10. Fuster V, Jang IK. Role of platelet-inhibitor agents in coronary artery disease. In: Topol EJ ed. Textbook of interventional cardiology. 2nd ed. Vol. 1. Philadelphia: W.B. Saunders, 1994: pp. 3-22.
11. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325-338.
12. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet glycoprofein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991;614:193-213.
13. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268:1066-1073.
14. Gould RJ, Polokoff MA, Friedman PA, et al. Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 1990;195:168-171.
15. Dennis MS, Henzel WJ, Pitti RM, et al. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: Evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1990;87:2471-2475.
16. Scarborough RM, Rose JW, Naughton MA, et al. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem 1993;268:1058-1065.
17. Gan ZR, Gould RJ, Jacobs JW, et al. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem 1988;263:19827-19832.
18. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30-33 .
19. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: A versatile cell recognition signal. Cell 1986;44:517-518.
20. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268:1066-1073.
21. Barker PL, Bullens S, Bunting S, et al. Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992;35:2040-2048.
22. Cox D, Aoki T, Seki J, et al. The pharmacology of the integrins. Med Res Rev 1994;14:195-228.
23. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
24. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition following intravenous administration of a peptide glycoprotein IIb/IIIa/ inhibitor during percutaneous coronary intervention: Results of a dose finding study. Am Heart J, in press, 1995.
25. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 1984;23:1767-1774.
26. Kloczewiak M, Timmons S, Hawiger J. Recognition site for the platelet receptor is present on the 15-residue carboxyterminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res 1983;29:249-255.
27. Cohen I, Burk DL, White JG. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb-IIIa complex on the development of dot tension. Blood 1989;73:1880-1887.
28. Altieri DC, Edgington TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol 1988;141:2656-2660.
29. Coller BS, Peerschke EI, Seligsohn U, et al. Studies on the binding of an alloimmune and two murine monoclonal antibodies to the platelet glycoprotein IIb-IIIa complex receptor. J Lab Clin Med 1986;107:384-392.
30. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-108.
31. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994;343:881-886.
32. The EPIC Investigators. Use of a monoclonal antibody direct ed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:955-961.
33. Tcheng JE, Lincoff AM, Sigmon KN, et al. Platelet glycoprotein IIb/IIIa inhibition with integrelin during percutaneous coronary intervention: The IMPACT II Trial (Abstract). Circulation 1995;92.
34. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993;22:381-389.
35. Ohman EM, Kleiman NS, Talley JD, et al. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction (Abstract). Circulation 1994;90:I-564.
36. Simoons ML, de Boer MJ, van den Brand MJ, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
37. Schulman SP, Goldschmidt-Clermont PJ, Navetta FI, et al. Integrelin in unstable angina: A double-blind randomized trial (Abstract). Circulation 1993;88:I-608.
38. Theroux P, Kouz S, Knudtson ML, et al. A randomized double-blind controlled trial with the nonpeptidic platelet GP IIb/IIIa antagonist RO 44-9883 in unstable angina (Abstract). Circulation 1994;90:I-232.